Vascular endothelial growth factor A: friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections?
Mieke A. van der Mescht, Helen C. Steel, Ronald Anderson, Theresa M. Rossouw · 2025
Read Vascular endothelial growth factor A: friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections? by Mieke A. van der Mescht, Helen C. Steel, Ronald Anderson, Theresa M. Rossouw (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11850333.txt.
Description
Mieke van der Mescht and co-authors weigh in a review dated 2024 whether a vessel growth factor is friend or foe in HIV and COVID-19. VEGF-A drives blood vessel growth and upkeep, and both HIV and the COVID-19 virus batter the vessel lining. The review first sketches vessel balance and growth, then the triangle of low oxygen, this factor, and inflammation.
For COVID-19, the virus's grip on two cell receptors lifts VEGF-A, feeding clotting, leaky vessels, and inflammation. HIV attacks differently: its tat protein mimics the factor at its main receptor and boosts a partner receptor. Together in co-infection, the authors propose, immune cells pour out the factor after vessel damage switches on a low oxygen sensor. Trials of blocking the factor eased oxygen needs in COVID-19 care. Yet blocking both its receptors could backfire, and the review ends on that caution.
Catalog record
| CREATOR | Mieke A. van der Mescht, Helen C. Steel, Ronald Anderson, Theresa M. Rossouw |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |